Ultragenyx Pharmaceutical Announces Two FDA Approvals and Phase 3 Trial Discontinuation

Ultragenyx Pharmaceutical Inc. has announced two new FDA approvals for its therapies: GENGLYCOS for Glycogen Storage Disease Type Ia and FAYUVI for Sanfilippo Syndrome Type A. Concurrently, the company is discontinuing its GTX-102 Phase 3 trial due to disappointing results and plans significant cost reductions.